Clinical evidence summary Gastrointestinal health Bifidobacterium longum 35624™

Explore the clinical evidence behind Bifidobacterium longum 35624™, a probiotic strain supported by decades of gastrointestinal research. This evidence summary reviews the role of the gut microbiome in irritable bowel syndrome (IBS), the strain's proposed immunoregulatory mechanisms, and findings from randomized controlled trials and real-world studies in adults and children with IBS.

Designed for healthcare professionals, this report highlights guideline recognition, symptom-focused outcomes, and the growing evidence base for targeted microbiome interventions. Learn how B. longum 35624™ has been investigated across key IBS symptoms, including abdominal pain, bloating, bowel habit dissatisfaction, and quality of life, while maintaining a well-documented safety profile.

• Comprehensive clinical evidence for Bifidobacterium longum 35624™ in irritable bowel syndrome (IBS), including randomized controlled trials and real-world observational studies.
• Insights into the gut microbiome and IBS, exploring how targeted probiotic strains may support symptom management through microbiome modulation.
• Review of guideline and expert recommendations highlighting the evidence supporting B. longum 35624™ for IBS symptom management.
• Evaluation of key patient-relevant outcomes, including abdominal pain, bloating, bowel movements, passage of gas, and quality of life.
• Evidence-backed safety and tolerability profile, supported by clinical studies and post-marketing experience.